![Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-019-49250-6/MediaObjects/41598_2019_49250_Fig2_HTML.png)
Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients
![Frontiers | Cause-Specific Mortality Among Survivors From T1N0M0 Renal Cell Carcinoma: A Registry-Based Cohort Study Frontiers | Cause-Specific Mortality Among Survivors From T1N0M0 Renal Cell Carcinoma: A Registry-Based Cohort Study](https://www.frontiersin.org/files/Articles/604724/fonc-11-604724-HTML/image_m/fonc-11-604724-g001.jpg)
Frontiers | Cause-Specific Mortality Among Survivors From T1N0M0 Renal Cell Carcinoma: A Registry-Based Cohort Study
![Incidence and mortality of kidney cancer: temporal patterns and global trends in 39 countries | Scientific Reports Incidence and mortality of kidney cancer: temporal patterns and global trends in 39 countries | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-017-15922-4/MediaObjects/41598_2017_15922_Fig1_HTML.jpg)
Incidence and mortality of kidney cancer: temporal patterns and global trends in 39 countries | Scientific Reports
![Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial | Nature Medicine Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial | Nature Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01694-6/MediaObjects/41591_2022_1694_Fig1_HTML.png)
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial | Nature Medicine
![Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-5900-1/MediaObjects/12885_2019_5900_Fig3_HTML.png)
Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text
![Changes in therapy and survival of metastatic renal cell carcinoma in Estonia | BMC Cancer | Full Text Changes in therapy and survival of metastatic renal cell carcinoma in Estonia | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-020-6685-y/MediaObjects/12885_2020_6685_Fig1_HTML.png)
Changes in therapy and survival of metastatic renal cell carcinoma in Estonia | BMC Cancer | Full Text
![Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib - Clinical Genitourinary Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib - Clinical Genitourinary](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/04f3cd1a-7ada-455e-84a4-4f0f15bcbde5/gr1_lrg.jpg)
Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib - Clinical Genitourinary
![Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-5900-1/MediaObjects/12885_2019_5900_Fig4_HTML.png)
Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text
![Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-5900-1/MediaObjects/12885_2019_5900_Fig2_HTML.png)
Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text
![The number of metabolic features as a significant prognostic factor in patients with metastatic renal cell carcinoma | Scientific Reports The number of metabolic features as a significant prognostic factor in patients with metastatic renal cell carcinoma | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-63816-9/MediaObjects/41598_2020_63816_Fig1_HTML.png)
The number of metabolic features as a significant prognostic factor in patients with metastatic renal cell carcinoma | Scientific Reports
![Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/684b750a-03b5-4494-b310-768504324d01/gr1.jpg)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology
![The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer | BMC Cancer | Full Text The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-6311-z/MediaObjects/12885_2019_6311_Fig3_HTML.png)
The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer | BMC Cancer | Full Text
![Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-5900-1/MediaObjects/12885_2019_5900_Fig1_HTML.png)
Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis | BMC Cancer | Full Text
![Overall survival curves for (A) all 140 patients with metastatic renal... | Download Scientific Diagram Overall survival curves for (A) all 140 patients with metastatic renal... | Download Scientific Diagram](https://www.researchgate.net/profile/Jun-Teishima/publication/263702696/figure/fig2/AS:667619061411855@1536184196912/Overall-survival-curves-for-A-all-140-patients-with-metastatic-renal-cell-carcinoma-and.png)
Overall survival curves for (A) all 140 patients with metastatic renal... | Download Scientific Diagram
![Kaplan-Meier survival analyses of patients with metastatic renal cell... | Download Scientific Diagram Kaplan-Meier survival analyses of patients with metastatic renal cell... | Download Scientific Diagram](https://www.researchgate.net/publication/304249872/figure/fig1/AS:560774998433793@1510710586837/Kaplan-Meier-survival-analyses-of-patients-with-metastatic-renal-cell-carcinoma-treated.png)
Kaplan-Meier survival analyses of patients with metastatic renal cell... | Download Scientific Diagram
![Overall survival for patients with progressive metastatic renal cell... | Download Scientific Diagram Overall survival for patients with progressive metastatic renal cell... | Download Scientific Diagram](https://www.researchgate.net/publication/7781128/figure/fig2/AS:601588360032308@1520441250678/Overall-survival-for-patients-with-progressive-metastatic-renal-cell-carcinoma-treated.png)
Overall survival for patients with progressive metastatic renal cell... | Download Scientific Diagram
![Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry - ScienceDirect Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419353566-gr1.jpg)